ABCODIA LAUNCHES COLORECTAL CANCER BIOMARKER INITIATIVE AND SEEKS INTERNATIONAL COLLABORATIONS
Abcodia, a company engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening, has announced the extension of its pancreatic cancer initiative into the area of colorectal cancer. Abcodia is now seeking to collaborate internationally to apply its unique prospective serum biobank of over 500,000 samples to discover and validate early stage molecular biomarkers and ultimately improve the diagnosis of colorectal cancer.
Colorectal (bowel) cancer is the third most common cancer in the USA, with the second highest number of cancer-related deaths. Early screening and diagnosis, before it spreads to other major organs is crucial for reducing death rates.
Abcodia has exclusive access to the UKCTOCS biobank that was created at University College London. Among the 202,000 initially healthy volunteers who have donated serum, more than 1,800 subjects have gone on to develop colorectal cancer; over 400 more have been diagnosed with benign and in-situ colorectal neoplasms. Detailed histology and pathology reports are available, as well as significant demographic data relating to age, ethnicity and lifestyle.
“We believe that our unique prospective collection of serum samples and data will be of great interest to those who share our passion in developing biomarkers for the early detection of colorectal cancer. Working with us and our collection of serum donated from volunteers before confirmed diagnosis means significant savings in time and money compared to conducting a de novo prospective study to validate a biomarker for screening.” said Julie Barnes, Abcodia’s CEO “We are looking for both commercial and academic partners.”
Abcodia is an innovative company engaged in the validation and discovery of molecular biomarkers. With its unique longitudinal serum biobank and partnerships with UCL, technology platform providers and leading commercial diagnostic companies, Abcodia is able to support the end-to-end diagnostic development process.
Please contact Press Officer, Ellee Seymour on 07939 811961 or by email
Get in touch
To find out more about this unique resource and collaboration opportunities, please contact us